Back to search results

Home Rehabilitation for Pulmonary Arterial Hypertension

This study is looking at whether a home rehabilitation program can help people with Pulmonary Arterial Hypertension (PAH). If you join, you would either receive daily exercise messages with heart rate guidance, or daily general messages. Researchers want to see if the exercise messages can lower your "cardiac effort" (how hard your heart works during a 6-minute walk test) and improve your quality of life over 3 months. To be eligible, you must be an adult (18+) with PAH, already receiving care at the University of Rochester Medical Center Pulmonary Hypertension Clinic, and on a stable dose of PAH medication for at least 30 days. This research could help improve how PAH is managed in the future.

Study design
This is an interventional study planning to enroll 55 participants. It compares a home exercise program to standard care.
What's involved
Participants will receive daily messages for 3 months. The study measures changes in cardiac effort from baseline to 3 months.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for 3 months, based on the primary endpoint timeframe.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06477640

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

Active, Not Recruiting
NAAges 18+InterventionalTreatment
University of Rochester
~55 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:ExerciseStandard of Care

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean change in cardiac effort
Measured over baseline to 3 months

Conditions

Pulmonary Arterial Hypertension PAH

Explore related trials

Pulmonary Arterial Hypertension

NCT06477640

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Rochester Medical Center

    Rochester, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.
Adult patients (\>18 years old) with right heart catheterization confirmed pulmonary hypertension (PAH) on stable vasodilator dosing for at least 30 days. No planned titrations will occur during the 12-week study. If during the study, the treating physician feels it is necessary for safety reasons to adjust dosing, the subject will remain in their assigned group.
Access to a smart phone or email to receive daily messages. If patients do not have access to either, we will offer a smartphone with cellular service for use during the study to receive daily messages.
Clinically stable by the investigator (i.e., we will not enroll patients who endorse ongoing improvement or clinical worsening at enrollment).
The treating investigator (Dr. Lachant or Dr. White) will review the clinical data of an eligible patient and establish them as safe to participate prior to approaching the patient for enrollment (i.e. not in decompensated heart failure or with recurrent pre-syncopal episodes prior to enrollment).

Exclusion

Pregnancy.
Pulmonary Hypertension Groups 2-5.
Resting tachycardia \>120 beats/m during screening.
Inability to walk.
WHO Functional Class IV
Lack of access to email or text messaging.
Inability to follow daily instructions. including the two home 6-minute walk tests during the initial monitoring period. This is to show compliance with the protocol.
Participating in a self-reported rehabilitation or exercise program.
Oxygen therapy of more than 6 L/min at rest.
Principal Investigator discretion

What this trial measures

  • Mean change in cardiac effortbaseline to 3 months

    Cardiac effort is the number of heartbeats used during the a six minute walk test divided by walk distance